Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

The firm will focus on programs for MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic right ventricular cardiomyopathy.